Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40% of people will meet response criteria. We therefore undertook a systematic review and meta-analysis of global literature on clozapine augmentation strategies. Methods: We systematically reviewed PubMed, PsycInfo, Embase, Cochrane Database, Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database for randomised control trials of augmentation strategies for clozapine resistant schizophrenia. We undertook pairwise meta-analyses of within-class interventions and, where possible, frequentist mixed treatment comparisons to differentiate treatment effectiveness Results: We identified 46 studies of 25 interventions. On pairwise meta-analyses, the most effective augmentation agents for total psychosis symptoms were aripiprazole (standardised mean difference: 0.48; 95% confidence interval: −0.89 to −0.07) fluoxetine (standardised mean difference: 0.73; 95% confidence interval: −0.97 to −0.50) and, sodium valproate (standardised mean difference: 2.36 95% confidence interval: −3.96 to −0.75). Memantine was effective for negative symptoms (standardised mean difference: −0.56 95% confidence interval: −0.93 to −0.20). However, many of these results included poor-quality studies. Single studies of certain antipsychotics (penfluridol), antidepressants (paroxetine, duloxetine), lithium and Ginkgo biloba showed potential, while electroconvulsive therapy was highly promising. Mixed treatment comparisons were only possible for antipsychotics, and these gave similar results to the pairwise meta-analyses. Conclusions: On the basis of the limited data available, the best evidence is for the use of aripiprazole, fluoxetine and sodium valproate as augmentation agents for total psychosis symptoms and memantine for negative symptoms. However, these conclusions are tempered by generally short follow-up periods and poor study quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 2×
“…Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations for the background, search strategy, methods, results, discussion and conclusions (Higgins and Green, 2011) including the Extension Statement for Incorporating Network Meta-analyses (Hutton et al., 2015).”
The nuts and bolts of PROSPERO: an international prospective register of systematic reviews
Booth, A., Clarke, M., Dooley, G., Ghersi, D., Moher, D., Petticrew, M., & Stewart, L. (2012) · Systematic Reviews · doi:10.1186/2046-4053-1-2 · Cited by 1,433 · cited 2×
“This study was registered with PROSPERO (registration number: CRD42016033279), an international database of prospectively registered systematic reviews (Booth et al., 2012).”
Clozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
The impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141
Self-citationShould we search Chinese biomedical databases when performing systematic reviews?
Cohen, J. F., Korevaar, D. A., Wang, J., Spijker, R., & Bossuyt, P. M. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0017-3 · Cited by 76 · cited 1×
“One strength of our search methodology was the inclusion of studies from Chinese databases (Cohen et al., 2015).”
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Self-citationFirth, J., Teasdale, S. B., Allott, K., Siskind, D., Marx, W., Cotter, J., Veronese, N., Schuch, F., Smith, L., Solmi, M., et al. (2019) · World Psychiatry · doi:10.1002/wps.20672 · Cited by 214
Self-citationCorrell, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022) · CNS Drugs · doi:10.1007/s40263-022-00932-2 · Cited by 162
Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis
Chen, S.-Y., Ravindran, G., Zhang, Q., Kisely, S., & Siskind, D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00612-8 · Cited by 66
“Amisulpride/sulpiride augmentation may allow for a reduction in total clozapine dosage, although a recent meta-analysis of augmentation of clozapine-refractory schizophrenia did not find a reduction of psychotic symptoms with amisulpride/ sulpiride [56].”
ResultSelf-citation
Metadata
- Authors
- Siskind, D. J., Lee, M., Ravindran, A., Zhang, Q., Ma, E., Motamarri, B., & Kisely, S.
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2018-05-06
- Volume
- 52
- Issue
- 8
- Pages
- 751-767
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2801632555
- Cited by
- 139
- References
- 7
- FWCI
- 2.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. https://app.cochat.ai/papers/10.1177/0004867418772351
- The paper
- Siskind, D. J., Lee, M., Ravindran, A., Zhang, Q., Ma, E., Motamarri, B., & Kisely, S. (2018). Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1177/0004867418772351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.